Project 2: Endoscopic Photodynamic and Combination Therapy for Local and Metastatic Pancreatic Tumors

项目2:内镜光动力及联合治疗局部及转移性胰腺肿瘤

基本信息

  • 批准号:
    9149695
  • 负责人:
  • 金额:
    $ 20.78万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2001
  • 资助国家:
    美国
  • 起止时间:
    2001-08-09 至
  • 项目状态:
    未结题

项目摘要

SUMMARY OF PROJECT 2 The goal of this project is to transform the management of pancreatic cancer (PanCa), a devastating disease that is most often diagnosed late, when curative therapies are no longer possible. Our strategy is to target the disease at three key stages: premalignant, locally advanced and metastatic, using photodynamic therapy (PDT) in combination with systemic therapy. We will build on our previous findings of PDT-induced tumor necrosis in PanCa patients, developing new treatment strategies that combine PDT with appropriately scheduled systemic chemotherapy to treat local and metastatic disease. We will also explore new treatment options for early pancreatic malignancies and precursor lesions, including intraductal papillary mucinous neoplasms (IPMN) and mucinous cystic neoplasms (MCN) from which many PanCa arise. Following on from our phase I clinical studies of CT-guided percutaneous PDT for locally advanced PanCa, Project 2 will move to the minimally invasive approach of endoscopic ultrasound (EUS)-guided PDT, with the potential for outpatient therapy with improved safety and healthcare costs. The goals will be realized in three aims. AIM 1 will establish, in a phase II study, the efficacy of EUS-PDT using verteporfin (benzoporphyrin, BPD) to ablate solid tumors of the pancreas. Clinical contrast CT-based treatment planning will be used to deliver patient-specific PDT. This aim will also establish the safety of giving chemotherapy almost immediately after PDT. AIM 2 will evaluate the novel combination of PDT and MM-398 (liposomal irenotecan, a topoisomerase inhibitor in phase III trials for metastatic PanCa), using the optimized treatment schedule identified in Aim 1 of Project 3 in collaboration with Merrimack Pharma. The hypothesis for the basis of synergistic mechanisms is that MM-398 reduces hypoxia and enhances PDT, while PDT destroys ABCG2 transporters and enhances MM-398 retention. Since single therapies alone are ineffective in PanCa, it is hypothesized that this combination strategy will enhance survival of patients who have locally advanced and/or metastatic disease. In AIM 3 we will study the efficacy of EUS-PDT in the treatment of premalignant cystic tumors of the pancreas. We will establish the use of fluorescence dosimetry and pre-PDT contrast CT to maximize PDT-induced cyst ablation. The immediate impact of this project will be to improve the care of patients with PanCa, and more broadly the findings will establish a clinical framework to translate new nanomedicine and combination-based targeted therapeutic discoveries for cancer. Potential public health benefits: The clinical studies described in Aims 1 and 2 provide new minimally invasive treatment options aimed at improving the length and quality of life in patients with PanCa. In Aim 3, we will develop a new ablative treatment option for patients with pancreatic cystic tumors, which will reduce the inconvenience and anxiety for patients of serial imaging and need for long-term follow up or surgery, with significant cost-savings.
项目2概要 该项目的目标是改变胰腺癌(PanCa)的管理,这是一种毁灭性的疾病 这通常是诊断晚,当治愈性治疗不再可能。我们的策略是针对 疾病的三个关键阶段:癌前病变,局部晚期和转移,使用光动力疗法 (PDT)与全身治疗相结合。我们将建立在我们以前的发现PDT诱导肿瘤 PanCa患者的坏死,开发新的治疗策略,将联合收割机PDT与适当的 定期全身化疗治疗局部和转移性疾病。我们还将探索新的治疗方法 早期胰腺恶性肿瘤和前驱病变的选择,包括导管内乳头状粘液性 肿瘤(IPMN)和粘液性囊性肿瘤(MCN),许多PanCa都是由其产生的。继 我们的CT引导经皮PDT治疗局部晚期PanCa的I期临床研究,项目2将转移到 内镜超声(EUS)引导PDT的微创方法,具有门诊患者的潜力 具有改善的安全性和医疗保健成本的治疗。这些目标将在三个目标中实现。AIM 1将 在II期研究中,确定使用维替泊芬(苯并卟啉,BPD)的EUS-PDT消融固体的功效, 胰腺肿瘤基于临床对比CT的治疗计划将用于提供患者特异性 PDT。这一目标也将确立PDT后几乎立即给予化疗的安全性。AIM 2将 评价PDT和MM-398(脂质体irenotecan,一种拓扑异构酶抑制剂, 转移性PanCa的III期试验),使用2009年项目3目标1中确定的优化治疗方案, 与梅里马克制药公司合作。协同机制基础的假设是MM-398 减少缺氧并增强PDT,而PDT破坏ABCG 2转运蛋白并增强MM-398 潴留由于单一疗法对PanCa无效,因此假设这种联合疗法 该策略将提高患有局部晚期和/或转移性疾病的患者的存活率。在AIM 3中, 将研究EUS-PDT治疗胰腺癌前囊性肿瘤的疗效。我们将 建立荧光剂量测定法和PDT前对比CT的使用,以最大化PDT诱导的囊肿消融。 该项目的直接影响将是改善PanCa患者的护理,更广泛地说, 研究结果将建立一个临床框架,以翻译新的纳米医学和基于组合的靶向 癌症的治疗发现 潜在的公共卫生益处:目标1和2中描述的临床研究提供了新的最低限度的 旨在改善PanCa患者的寿命和生活质量的侵入性治疗选择。在目标3中,我们 将为胰腺囊性肿瘤患者开发一种新的消融治疗选择, 对连续成像患者的不便和焦虑,需要长期随访或手术, 显著的成本节约。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Stephen Pereira其他文献

Stephen Pereira的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Stephen Pereira', 18)}}的其他基金

Clinical Photodynamic Therapy for Pancreatic and Biliary Tract Cancer
胰腺癌和胆道癌的临床光动力治疗
  • 批准号:
    8103132
  • 财政年份:
    2001
  • 资助金额:
    $ 20.78万
  • 项目类别:
Project 2: Endoscopic Photodynamic and Combination Therapy for Local and Metastatic Pancreatic Tumors
项目2:内镜光动力及联合治疗局部及转移性胰腺肿瘤
  • 批准号:
    9407016
  • 财政年份:
    2001
  • 资助金额:
    $ 20.78万
  • 项目类别:
Clinical Photodynamic Therapy for Pancreatic and Biliary Tract Cancer
胰腺癌和胆道癌的临床光动力治疗
  • 批准号:
    8374933
  • 财政年份:
    2001
  • 资助金额:
    $ 20.78万
  • 项目类别:
Clinical Photodynamic Therapy for Pancreatic and Biliary Tract Cancer
胰腺癌和胆道癌的临床光动力治疗
  • 批准号:
    8403909
  • 财政年份:
    2001
  • 资助金额:
    $ 20.78万
  • 项目类别:
Clinical Photodynamic Therapy for Pancreatic and Biliary Tract Cancer
胰腺癌和胆道癌的临床光动力治疗
  • 批准号:
    8208941
  • 财政年份:
    2001
  • 资助金额:
    $ 20.78万
  • 项目类别:
Clinical Photodynamic Therapy for Pancreatic and Biliary Tract Cancer
胰腺癌和胆道癌的临床光动力治疗
  • 批准号:
    7611507
  • 财政年份:
    2001
  • 资助金额:
    $ 20.78万
  • 项目类别:

相似海外基金

心房細動に対するPulsed Field Ablationの組織創傷治癒過程を明らかにする網羅的研究
阐明房颤脉冲场消融组织伤口愈合过程的综合研究
  • 批准号:
    24K11201
  • 财政年份:
    2024
  • 资助金额:
    $ 20.78万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Targeted ablation of cerebral atherosclerosis using supramolecular self-assembly
利用超分子自组装靶向消融脑动脉粥样硬化
  • 批准号:
    24K21101
  • 财政年份:
    2024
  • 资助金额:
    $ 20.78万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
遅延造影心臓MRIによる心房細動Ablation冷却効果の比較:28 vs. 31 mm Cryoballoon
使用延迟对比增强心脏 MRI 比较房颤消融冷却效果:28 毫米与 31 毫米 Cryoballoon
  • 批准号:
    24K11281
  • 财政年份:
    2024
  • 资助金额:
    $ 20.78万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
CAREER: Heat Penetration Depth and Direction Control with Closed-Loop Device for Precision Ablation
职业:利用闭环装置控制热穿透深度和方向,实现精确烧蚀
  • 批准号:
    2338890
  • 财政年份:
    2024
  • 资助金额:
    $ 20.78万
  • 项目类别:
    Continuing Grant
Collaborative Research: RUI: Frontal Ablation Processes on Lake-terminating Glaciers and their Role in Glacier Change
合作研究:RUI:湖终止冰川的锋面消融过程及其在冰川变化中的作用
  • 批准号:
    2334777
  • 财政年份:
    2024
  • 资助金额:
    $ 20.78万
  • 项目类别:
    Continuing Grant
Collaborative Research: RUI: Frontal Ablation Processes on Lake-terminating Glaciers and their Role in Glacier Change
合作研究:RUI:湖终止冰川的锋面消融过程及其在冰川变化中的作用
  • 批准号:
    2334775
  • 财政年份:
    2024
  • 资助金额:
    $ 20.78万
  • 项目类别:
    Continuing Grant
InSPACE-VT_Development and Validation of Virtual Pace Mapping to Guide Catheter Ablation of Ventricular Tachycardia
InSPACE-VT_虚拟起搏测绘的开发和验证以指导室性心动过速导管消融
  • 批准号:
    EP/Z001145/1
  • 财政年份:
    2024
  • 资助金额:
    $ 20.78万
  • 项目类别:
    Fellowship
Collaborative Research: RUI: Frontal Ablation Processes on Lake-terminating Glaciers and their Role in Glacier Change
合作研究:RUI:湖终止冰川的锋面消融过程及其在冰川变化中的作用
  • 批准号:
    2334776
  • 财政年份:
    2024
  • 资助金额:
    $ 20.78万
  • 项目类别:
    Continuing Grant
MRI: Acquisition of a Laser Ablation - Inductively Coupled Plasma - Triple Quadrupole - Mass Spectrometer (LA-ICP-QQQ-MS) System For Research and Education
MRI:获取用于研究和教育的激光烧蚀 - 电感耦合等离子体 - 三重四极杆 - 质谱仪 (LA-ICP-MS/MS) 系统
  • 批准号:
    2320040
  • 财政年份:
    2023
  • 资助金额:
    $ 20.78万
  • 项目类别:
    Standard Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了